Recently, there have been many negative messages here trying to scare investors by planting confusion and doubts on their minds. The ultimate aim is to bring down the share price of RXII.
I have been conducting my own DD on RXII for over a year and it is a good time for me to share strength and value of this company:
(1) Finance: Cash $6.2M+$16M from private placement=$22.2M. Based on current burn rate, this should be adequate for RXI-109 to commplete Phase 2 clinical trial around 2014.
(2) Technology: Dr. Mello (Nobel Price winner) is the leader of RXII's scientific team. RNAi works based on Dr. Mello's work. RXI-109 plus 3 delivery systems, fully patented, works in reducing demal scars on human and proven safe from Phase 1a results.
(3) Marketing: Once approves by the FDA, RXI-109 can be distributed via OPKO's skin care distribution channels.
(4) Management: RXII CEO Geert Cauwenbergh has a long track record of business success. Philip Frost is a multi-billionaire and Chairman of the Board of Teva a major multi-national pharma with $34 billion market-cap.
These corporate values have been giving me strength to establish a position in RXII and stay with it for the next 3 to 4 years.